Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

30 Sept 2008

Abstract excerpt

Receptor tyrosine kinases are often aberrantly activated in human malignancies and contribute to cancer development and progression. Specific receptor tyrosine kinase inhibitors have been shown to be clinically effective therapies in subsets of cancer patients with either hematologic or solid tumors. Activation of the hepatocyte growth factor (HGF)/MET signaling pathway has been found to play a critical role in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Liver physiology and pathology
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18829470
DOI: 10.1158/1078-0432.ccr-08-0071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in CancerPMID 18829470Read ↗

The current state of molecularly targeted drugs targeting HGF/Met.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesisSemantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesSemantic proximity Read ↗

HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.